Jigao Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jigao Sun has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Taixian Li
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications - Weiheng Chen
Third Affiliated Hospital of Beijing University of Chinese Medicine; Engineering Research Center of Chinese Orthopaedics and Sports Rehabilitation Artificial Intelligent, Ministry of Education Beijing China
2 shared publications - Zhipeng Xue
The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, CHINA
2 shared publications Jiawen Zhang
Traumatic Joint Surgery Department, Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China
1 shared publication- Mengge Song
Wangjing Hospital Academy of Chinese Medical Sciences Beijing China
1 shared publication - Qianglong Chen
Guizhou University of Traditional Chinese Medicine Guiyang China
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (9) , 1159-1175
Diagnostic biomarkers for non-traumatic osteonecrosis of the femoral head
Aims: Many studies have focused on identifying specific biomarkers for the early diagnosis of non-traumatic osteonecrosis of the femoral head (NONFH). This systematic review aims to summarize biomarkers associated with the diagnosis and progression prediction of NONFH, thereby providing a molecular level foundation for clinical diagnosis and targeted treatment. Methods: Following the PRISMA guidelines for systematic reviews, we comprehensively searched original English-language articles published between January 2015 and December 2025 in the Web of Science and PubMed databases. Studies were selected based on the PICOS framework. Extracted data included study design, methodologies, sample sources, identified biomarkers, predictive performance, and the potential pathological pathways involved. Results: Overall, 15 studies were included, reporting a total of 52 biomarkers, all derived from blood samples. Biomarkers from eight studies were used to reflect NONFH progression, while those from seven studies were using for diagnostic prediction purposes. All biomarkers demonstrated favourable predictive performance, with six studies providing external validation. The predictive model comprising ICAM1, NR3C1, IKBKB, and CD4 showed promising performance, with area under the receiver operating characteristic curve (AUC) values each reaching 1.00. Based on their core functions, the biomarkers were categorized into seven functional groups: immune-inflammatory activation and response, signal transduction and regulation, molecular metabolism and energy homeostasis, vascular function and coagulation, oxidative stress, pyroptosis and autophagy, and RNA regulatory. Conclusion: Biomarkers for NONFH exhibit considerable potential for early diagnosis and disease progression prediction in the Chinese population. The pathogenesis of NONFH involves a multifaceted pathological process in which various components interact and synergistically exacerbate the condition. This indicates that future therapeutic strategies should adopt a multitarget, multipathway synergistic intervention approach. Cite this article: Bone Joint Res 2026;15(9):1159–1175.
- 21 September 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (9) , 1159-1175
Open AccessDiagnostic biomarkers for non-traumatic osteonecrosis of the femoral head
Aims: Many studies have focused on identifying specific biomarkers for the early diagnosis of non-traumatic osteonecrosis of the femoral head (NONFH). This systematic review aims to summarize biomarkers associated with the diagnosis and progression prediction of NONFH, thereby providing a molecular level foundation for clinical diagnosis and targeted treatment. Methods: Following the PRISMA guidelines for systematic reviews, we comprehensively searched original English-language articles published between January 2015 and December 2025 in the Web of Science and PubMed databases. Studies were selected based on the PICOS framework. Extracted data included study design, methodologies, sample sources, identified biomarkers, predictive performance, and the potential pathological pathways involved. Results: Overall, 15 studies were included, reporting a total of 52 biomarkers, all derived from blood samples. Biomarkers from eight studies were used to reflect NONFH progression, while those from seven studies were using for diagnostic prediction purposes. All biomarkers demonstrated favourable predictive performance, with six studies providing external validation. The predictive model comprising ICAM1, NR3C1, IKBKB, and CD4 showed promising performance, with area under the receiver operating characteristic curve (AUC) values each reaching 1.00. Based on their core functions, the biomarkers were categorized into seven functional groups: immune-inflammatory activation and response, signal transduction and regulation, molecular metabolism and energy homeostasis, vascular function and coagulation, oxidative stress, pyroptosis and autophagy, and RNA regulatory. Conclusion: Biomarkers for NONFH exhibit considerable potential for early diagnosis and disease progression prediction in the Chinese population. The pathogenesis of NONFH involves a multifaceted pathological process in which various components interact and synergistically exacerbate the condition. This indicates that future therapeutic strategies should adopt a multitarget, multipathway synergistic intervention approach. Cite this article: Bone Joint Res 2026;15(9):1159–1175.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 2168283
Acupotomy Therapy for Knee Osteoarthritis Pain: Systematic Review and Meta‐Analysis
Background and Purpose. Knee osteoarthritis (OA) is a major public health problem, and currently, few effective medical treatments exist. Chinese acupotomy therapy has been widely used for the treatment of knee OA in China. We conducted this systematic review and meta‐analysis to evaluate the efficacy of Chinese acupotomy in treating knee OA to inform clinical practice. Methods. We performed a comprehensive search on PubMed, the Cochrane Library, EMBASE, and four Chinese databases for articles published prior to June 2020. We included only randomized controlled trials (RCTs) that used acupotomy therapy as the major intervention in adults with knee OA, were published in either Chinese and English, included more than 20 subjects in each group, and included pain and function in the outcome measures. Knee OA was defined by the American College of Rheumatology or Chinese Orthopedic Association criteria in all studies. We extracted the visual analogue scale (VAS) pain score, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, the total effectiveness rate, the modified Japanese Orthopedic Association (JOA) activities of daily living score, and Lysholm’s score. We calculated the mean difference (MD) or risk ratio (RR) for all relevant outcomes. Meta‐analyses were conducted using random‐effects models when appropriate. Results. We identified 1317 potentially relevant studies, thirty‐two of which met the eligibility criteria and were conducted in China between 2007 and 2020. A total of 3021 knee OA patients (62.96% female, median age: 57 years, and median disease duration: 33 months) were included. The treatment duration ranged from 1 week to 5 weeks (median: 3 weeks). The typical acupotomy treatment involved releasing soft tissue adhesions and was performed once a week for 1–5 weeks until the pain was relieved. The control group treatments included acupuncture (8 studies), electroacupuncture (10 studies), sodium hyaluronate (8 studies), radiofrequency electrotherapy (1 study), and nonsteroidal anti‐inflammatory drugs (NSAIDs, 5 studies). The results from the meta‐analysis showed that acupotomy led to superior improvements in the VAS pain score (MD = −1.11; 95% confidence interval (CI), −1.51 to −0.71; p < 0.00001) and WOMAC pain score (MD = −2.32; 95% CI, −2.94 to −1.69; p < 0.00001), a higher total effectiveness rate (RR = 1.15; 95% CI, 1.09–1.21; p < 0.00001), and superior improvements in the JOA score (MD = 6.39; 95% CI, 4.11–9.76; p < 0.00001) and Lysholm’s score (MD = 12.75; 95% CI, 2.61–22.89; p = 0.01) for overall pain and function. No serious adverse events were reported. Conclusion. Chinese acupotomy therapy may relieve pain and improve function in patients with knee OA. Furthermore, rigorously designed and well‐controlled RCTs are warranted.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 2168283
Open AccessAcupotomy Therapy for Knee Osteoarthritis Pain: Systematic Review and Meta‐Analysis
Background and Purpose. Knee osteoarthritis (OA) is a major public health problem, and currently, few effective medical treatments exist. Chinese acupotomy therapy has been widely used for the treatment of knee OA in China. We conducted this systematic review and meta‐analysis to evaluate the efficacy of Chinese acupotomy in treating knee OA to inform clinical practice. Methods. We performed a comprehensive search on PubMed, the Cochrane Library, EMBASE, and four Chinese databases for articles published prior to June 2020. We included only randomized controlled trials (RCTs) that used acupotomy therapy as the major intervention in adults with knee OA, were published in either Chinese and English, included more than 20 subjects in each group, and included pain and function in the outcome measures. Knee OA was defined by the American College of Rheumatology or Chinese Orthopedic Association criteria in all studies. We extracted the visual analogue scale (VAS) pain score, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, the total effectiveness rate, the modified Japanese Orthopedic Association (JOA) activities of daily living score, and Lysholm’s score. We calculated the mean difference (MD) or risk ratio (RR) for all relevant outcomes. Meta‐analyses were conducted using random‐effects models when appropriate. Results. We identified 1317 potentially relevant studies, thirty‐two of which met the eligibility criteria and were conducted in China between 2007 and 2020. A total of 3021 knee OA patients (62.96% female, median age: 57 years, and median disease duration: 33 months) were included. The treatment duration ranged from 1 week to 5 weeks (median: 3 weeks). The typical acupotomy treatment involved releasing soft tissue adhesions and was performed once a week for 1–5 weeks until the pain was relieved. The control group treatments included acupuncture (8 studies), electroacupuncture (10 studies), sodium hyaluronate (8 studies), radiofrequency electrotherapy (1 study), and nonsteroidal anti‐inflammatory drugs (NSAIDs, 5 studies). The results from the meta‐analysis showed that acupotomy led to superior improvements in the VAS pain score (MD = −1.11; 95% confidence interval (CI), −1.51 to −0.71; p < 0.00001) and WOMAC pain score (MD = −2.32; 95% CI, −2.94 to −1.69; p < 0.00001), a higher total effectiveness rate (RR = 1.15; 95% CI, 1.09–1.21; p < 0.00001), and superior improvements in the JOA score (MD = 6.39; 95% CI, 4.11–9.76; p < 0.00001) and Lysholm’s score (MD = 12.75; 95% CI, 2.61–22.89; p = 0.01) for overall pain and function. No serious adverse events were reported. Conclusion. Chinese acupotomy therapy may relieve pain and improve function in patients with knee OA. Furthermore, rigorously designed and well‐controlled RCTs are warranted.
- Open Access
- 9 October 2019
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 14 (1) , 1-9
How to evaluate the clinical outcome of joint-preserving treatment for osteonecrosis of the femoral head: development of a core outcome set
Background: This study aimed to develop a core outcome set (COS) for clinical trials of joint-preserving treatment for osteonecrosis of the femoral head (ONFH), that is, to define a minimal set of outcomes that should be reported in such trials. Methods: A mixed research method was adopted in this study. First, clinical trials of hip preservation therapy were systematically researched and analyzed. Second, a three-round Delphi survey involving both doctors and patients was carried out to obtain the core outcome indicators. Round 1 was a modified Delphi questionnaire for doctors and patients to determine which outcomes are important to these stakeholders, round 2 determined what clinical evaluation core outcomes should be included for the joint-preserving treatment of ONFH, and round 3 determined how core outcomes should be measured. Finally, a consensus meeting was held to discuss and vote on the established COS. Results: The results of the systematic review showed that 42 outcome indicators were classified according to common signs and symptoms, quality of life, long-term outcomes, radiological evaluation, blood biochemistry, and indexes of safety. The three rounds of Delphi surveys completed the selection of indicators for the COS and the determination of the corresponding measurements. A total of 73 orthopedic doctors and 103 patients participated in round 1, and the top 10 indicators selected were basically the same. In round 2, 32 experts identified the following indicators: pain, range of motion (ROM) of hip flexion, walking distance, and stable rating of X-ray images. In round 3, 35 experts defined the measurement of each indicator. Finally, the consensus meeting identified the four indicators aforementioned that constituted the COS. The scores for pain, ROM of hip flexion, and walking distance are from 0 to 10; 0 represents the best scores, while 10 represents the most serious impairment. The stable rating of X-ray images is determined by the morphology of the femoral head and the change in the density of the necrotic area. Conclusions: We established a COS for hip-preserving treatment of ONFH that includes four indicators: pain, ROM of hip flexion, walking distance, and stable rating of X-ray images.
- 9 October 2019
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 14 (1) , 1-9
Open AccessHow to evaluate the clinical outcome of joint-preserving treatment for osteonecrosis of the femoral head: development of a core outcome set
Background: This study aimed to develop a core outcome set (COS) for clinical trials of joint-preserving treatment for osteonecrosis of the femoral head (ONFH), that is, to define a minimal set of outcomes that should be reported in such trials. Methods: A mixed research method was adopted in this study. First, clinical trials of hip preservation therapy were systematically researched and analyzed. Second, a three-round Delphi survey involving both doctors and patients was carried out to obtain the core outcome indicators. Round 1 was a modified Delphi questionnaire for doctors and patients to determine which outcomes are important to these stakeholders, round 2 determined what clinical evaluation core outcomes should be included for the joint-preserving treatment of ONFH, and round 3 determined how core outcomes should be measured. Finally, a consensus meeting was held to discuss and vote on the established COS. Results: The results of the systematic review showed that 42 outcome indicators were classified according to common signs and symptoms, quality of life, long-term outcomes, radiological evaluation, blood biochemistry, and indexes of safety. The three rounds of Delphi surveys completed the selection of indicators for the COS and the determination of the corresponding measurements. A total of 73 orthopedic doctors and 103 patients participated in round 1, and the top 10 indicators selected were basically the same. In round 2, 32 experts identified the following indicators: pain, range of motion (ROM) of hip flexion, walking distance, and stable rating of X-ray images. In round 3, 35 experts defined the measurement of each indicator. Finally, the consensus meeting identified the four indicators aforementioned that constituted the COS. The scores for pain, ROM of hip flexion, and walking distance are from 0 to 10; 0 represents the best scores, while 10 represents the most serious impairment. The stable rating of X-ray images is determined by the morphology of the femoral head and the change in the density of the necrotic area. Conclusions: We established a COS for hip-preserving treatment of ONFH that includes four indicators: pain, ROM of hip flexion, walking distance, and stable rating of X-ray images.